Orforglipron dosage chart: all six Foundayo strengths

The Foundayo chart

Six strengths and five moves. The first two moves are instructions. The rest are permissions, so where a person stops is a decision rather than a schedule.

The left column says at the fastest for a reason. The label does not print day ranges. It says to move up after at least 30 days on the current dose, so 17.2 mg is reachable on day 151 and not before. A slower climb is inside the instruction.

The first two moves are written as increase the dosage. From 5.5 mg upwards the wording changes to may be increased, based on treatment response and tolerability. That is why 4 of the six strengths are marked as a place to stop.

It matters because the top of this ladder is not like the others on this site. A Wegovy tablet has one dose the label calls maintenance. This label names 17.2 mg as a maximum and stops there.

The second ceiling, set by what else you take

One common class of medicine caps this drug at 9 mg, which deletes the top three strengths of the ladder above.

Read those four together and the shape is clear. Avoid the interacting medicine if you can. If you cannot, 9 mg is as high as the ladder goes, so 2 of the six strengths are off the table.

The other direction is stranger. A drug that speeds this one up does not lower the ceiling. The label says to watch whether the tablet is still working and to climb further if it is not.

The label does not provide a simple list of medicines that need this adjustment. Ask the person who prescribed it to check your current medicines.

How is the tablet taken?

Four rules, and the interesting part is the two that are absent. This tablet asks for no fasting window and no rule about water.

Compare that with the other GLP-1 tablet on sale. A semaglutide tablet has to be taken on an empty stomach, with no more than four ounces of water and nothing else to drink, and then nothing at all for thirty minutes. Orforglipron asks for none of that.

That is a difference between two documents, and nothing more. Neither label compares the two tablets, and neither does this page. The semaglutide tablet schedules carry the thirty-minute rule in the label’s own words.

What if you miss a day?

Take it. That sounds obvious, and it is the opposite of what the other GLP-1 tablet says to do.

The semaglutide tablet label says the other thing, in as many words.

Two GLP-1 tablets, two opposite instructions for the same morning. Nothing about either bottle tells you which rule is yours, so the answer is whichever label is on the one you were given.

The third rule is the one worth remembering. Miss a whole week and the escalation starts again lower down, because the ladder exists to keep the gut reactions in the next section manageable.

What the trials reported, dose by dose

3,155 adults over 72 weeks, in two placebo-controlled trials. Read down a column and the reactions the ladder exists to blunt are the ones that rise with the dose.

Three columns, six strengths. The trials tested 5.5, 9 and 17.2 mg, so nothing is reported for the 0.8, 2.5 or 14.5 mg tablets and no figure has been guessed for them here.

Nausea is the clearest read: 10% on placebo, 26% at 5.5 mg, 35% at the top. Headache barely moves at all, which is what a column looks like when the drug is not driving it.

Stopping is the other half of the question. 8% of treated patients quit over a reaction against 3% on placebo, and 5% of everyone treated quit over a gut reaction specifically. By dose that runs 6%, 9% and 10%.

Those are trial rates under trial conditions. They are not a forecast for one person, and the label says as much before it prints them.

The boxed warning says something unusual

It is the GLP-1 class warning about thyroid tumors in rodents. Its second sentence is that this drug did not cause them.

“Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.”

The warning opens with the class sentence, the one every GLP-1 carries.

Then it says the line above. Orforglipron is not a peptide, and the rodent studies do not land on it the same way.

The warning stays anyway, and the label says why in one line.

So the rule about who must not take it is the same as for the rest of the class.

The label also declines to recommend a test for it.

One more line sits above the dosing section and is easy to miss. This is a weight drug only. It has no approval for blood sugar, which is what both diabetes tablets on the other page are for.

The label changed in August, and one source has not caught up

A labeling supplement was approved on 4 August 2026, and it deleted a storage instruction. The version published on DailyMed is still the April one.

The April labeling carried this. The current one does not carry it at all, in any of the three places it used to appear.

What survives is the ordinary line.

We are not saying why it changed. FDA does not publish a reason, and reading one into a deletion would be inventing a finding. What we can say is that it went.

The part worth knowing is where the two versions live. The current one is the PDF in FDA’s own approval record. DailyMed, which is where most links to “the label” land, was still serving version 5 from 2026-04-03 on 2026-08-13 — the April document, storage instruction and all.

Nobody is late. FDA gives a company two weeks from an approval letter to file the new structured labeling, and on the day we read this that window was still open. But two federal sources disagreed about one instruction, so a page that publishes labels should say which it read.

What is on the bottle

One brand, one company, one application, and all six strengths shipping since the day it was approved.

• Sold as Foundayo under NDA 220934, approved 2026-04-01 — the date on the signed FDA approval letter, and the day marketing started.
• Strengths: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. All six appear in FDA’s drug code directory as being marketed, in bottles of 30 tablets.
• Approved for: Weight reduction and keeping it off, in adults, alongside a reduced-calorie diet and more activity.
• The first GLP-1 tablet that is not a peptide. It is approved for weight only, and its label says plainly that taking it alongside another GLP-1 medicine is not recommended.

It is the first GLP-1 tablet that is not a peptide, which is the reason it needs no absorption trick and no fasting window. The pill against the shot covers what a daily tablet asks of a person that a weekly injection does not.

What this chart cannot tell you

Five things, and the last one is the one people get wrong most often.

• This is the schedule a label prints, not a schedule for anyone in particular. Every step above the third is written as something a prescriber may do rather than will do, and where it stops is a decision about you that no document can make in advance.
• The reaction table reports three of the six strengths, because those are the three the two trials tested. Nothing is reported for the 0.8, 2.5 or 14.5 mg tablets and no figure has been filled in for them here.
• The dosing information does not say how much weight anyone lost or compare this tablet with another drug. Those answers come from results trials, not from a dosing section.
• CMS has not yet published an acquisition cost for this new product. We leave the price blank instead of substituting an older or unrelated figure.
• The milligrams on this tablet mean nothing on any other GLP-1. There is no conversion between orforglipron and semaglutide or tirzepatide, no regulator has published one, and the numbers being similar in size is a coincidence of chemistry rather than a scale.